Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939145 | 1.00 | DGAT1 (0.40) | DGAT1CYP1A2CYP2D6CTSSCTSK | |
| SCHEMBL28195825 | 1.00 | DGAT1 (0.40) | DGAT1CYP1A2CYP2D6CTSSCTSK | |
| SCHEMBL2330290 | 0.88 | DGAT1 (0.38) | DGAT1CYP1A2CYP2D6CTSSCTSK | |
| SCHEMBL25436173 | 0.88 | DGAT1 (0.38) | DGAT1CYP1A2CYP2D6CTSSCTSK | |
| SCHEMBL30185755 | 0.88 | DGAT1 (0.38) | DGAT1CYP1A2CYP2D6CTSSCTSK | |
| SCHEMBL28815007 | 0.86 | DGAT1 (0.36) | DGAT1CYP1A2CYP2D6CTSSCTSK | |
| SCHEMBL28199018 | 0.86 | DGAT1 (0.36) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL4907419 | 0.86 | DGAT1 (0.36) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL1536326 | 0.84 | DGAT1 (0.39) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL27797420 | 0.84 | DGAT1 (0.35) | DGAT1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177429-A1 | ORALLY ACTIVE PRODRUG OF GEMCITABINE | LAEVOROC CHEMOTHERAPY AG (CH) | 2025-06-05 | — | — | US | claimed |
| EP-4490165-A1 | ORALLY ACTIVE PRODRUG OF GEMCITABINE | Laevoroc Chemotherapy AG (CH) | 2025-01-15 | — | — | EP | claimed |
| CN-118891268-A | Orally active prodrugs of gemcitabine | 莱沃罗克化疗股份公司 | 2024-11-01 | — | — | CN | claimed |
| WO-2023170279-A1 | ORALLY ACTIVE PRODRUG OF GEMCITABINE | LAEVOROC CHEMOTHERAPY AG (CH) | 2023-09-14 | — | — | WO | claimed |
| CN-105263941-A | Alkyl esters of 2- { [ (2R,3S,5R) -5- (4-amino-2-oxo-2H-pyrimidin-1-yl) -3-hydroxy-tetrahydro-furan-2-ylmethoxy ] -phenoxy-phosphorylamino } -propionic acid, nucleoside inhibitors of HCV RNA-polymerase NS5B, processes for their preparation and their use | IVACHTCHENKO ALEXANDRE VASILIEVICH | 2016-01-20 | — | — | CN | claimed |
| CN-103103239-A | Method for synthesizing thymopentin by enzyme | UNIV SOUTH CHINA AGRICULT | 2013-05-15 | — | — | CN | claimed |
| CN-101044151-B | Antiviral 4'-azido-nucleosides | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | claimed |
| CN-101044151-A | Antiviral 4'-azido-nucleosides | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | CN | claimed |
| US-20250177429-A1 | ORALLY ACTIVE PRODRUG OF GEMCITABINE | LAEVOROC CHEMOTHERAPY AG (CH) | 2025-06-05 | — | — | US | disclosed |
| EP-4490165-A1 | ORALLY ACTIVE PRODRUG OF GEMCITABINE | Laevoroc Chemotherapy AG (CH) | 2025-01-15 | — | — | EP | disclosed |
| CN-118891268-A | Orally active prodrugs of gemcitabine | 莱沃罗克化疗股份公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4244221-A1 | PRODRUG OF PYRROLIDONE DERIVATIVES AS GLUCOKINASE ACTIVATOR | Hua Medicine (Shanghai) Ltd. (CN) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023170279-A1 | ORALLY ACTIVE PRODRUG OF GEMCITABINE | LAEVOROC CHEMOTHERAPY AG (CH) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023040937-A1 | PRODRUG OF PYRROLIDONE DERIVATIVES AS GLUCOKINASE ACTIVATOR | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-03-23 | — | — | WO | disclosed |
| CN-1703221-A | 2-alkyl- (2-amino-3-aryl-propionyl) -piperazine derivatives and related compounds as melanocortin receptor ligands for the treatment of obesity | PROCTER & GAMBLE (US) | 2005-11-30 | — | — | CN | disclosed |
| CN-1350525-A | 1,3,4-oxadiazole derivatives and process for producing the same | ONO PHARMACEUTICAL CO (JP) | 2002-05-22 | — | — | CN | disclosed |
| WO-1995030651-A1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID AMIDES AS MICROBIOCIDES | CIBA-GEIGY AG (CH) | 1995-11-16 | — | — | WO | disclosed |
| US-5047399-A | Hypotensive Agents | SCHERING CORPORATION (US) | 1991-09-10 | — | — | US | disclosed |
| US-4766109-A | HYPOTENSIVE AGENTS | SCHERING CORPORATION (US) | 1988-08-23 | — | — | US | disclosed |
| US-4146614-A | TREATMENT OF SCHIZOPHRENIA | STATE OF MICHIGAN (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177429-A1 | ORALLY ACTIVE PRODRUG OF GEMCITABINE | RNASE1, TYMP, DPYD | DGAT1 978/4885CYP1A2 1992/4885CYP2D6 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.